Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Paolo Strati, Alessandra Ferrajoli, Susan Lerner, Susan O’Brien, William Wierda, Michael J. Keating & Stefan Faderl. (2014) Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 55:4, pages 828-833.
Read now
Read now
Daphne R. Friedman. (2013) “Primum non nocere”: the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia. Leukemia & Lymphoma 54:3, pages 441-442.
Read now
Read now
Clive S. Zent, Wenting Wu, Deborah A. Bowen, Curtis A. Hanson, Adam M. Pettinger, Tait D. Shanafelt, Neil E. Kay, Jose F. Leis & Timothy G. Call. (2013) Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leukemia & Lymphoma 54:3, pages 476-482.
Read now
Read now
Eric van den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, Loïc Ysebaert, Pierre Feugier, Stéphane Leprêtre & Caroline Dartigeas. (2012) Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & Lymphoma 53:3, pages 362-370.
Read now
Read now
Reem Karmali, Melissa L. Larson, James E. Wooldridge, Stephanie A. Gregory, Teresa O'Brien, Jamile M. Shammo, Katherine Bueschel & Parameswaran Venugopal. (2011) Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leukemia & Lymphoma 52:11, pages 2097-2104.
Read now
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Read now
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now
Read now
Aref Al-Kali, William Wierda, Michael Keating & Susan O’Brien. (2010) Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). Journal of Blood Medicine 1, pages 115-122.
Read now
Read now
Articles from other publishers (7)
Ping Li, David Harris, Zhiming Liu, Uri Rozovski, Alessandra Ferrajoli, Yongtao Wang, Carlos Bueso-Ramos, Inbal Hazan-Halevy, Srdana Grgurevic, William Wierda, Jan Burger, Susan O'Brien, Stefan Faderl, Michael Keating & Zeev Estrov. (2014) STAT3-Activated GM-CSFRα Translocates to the Nucleus and Protects CLL Cells from Apoptosis. Molecular Cancer Research 12:9, pages 1267-1282.
Crossref
Crossref
A.X.S. Santos, J.E. Maia, P.M. Crespo, L.F. Pettenuzzo, J.L. Daniotti, F.M. Barbé-Tuana, L.M. Martins, V.M.T. Trindade, R. Borojevic & F.C.R. Guma. (2011) GD1a modulates GM-CSF-induced cell proliferation. Cytokine 56:3, pages 600-607.
Crossref
Crossref
Michaela Gruber, Karin Fleiss, Edit Porpaczy, Cathrin Skrabs, Alexander W. Hauswirth, Alexander Gaiger, Katrina Vanura, Daniel Heintel, Medhat Shehata, Christine Einberger, Renate Thalhammer, Christa Fonatsch & Ulrich J?ger. (2011) Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Annals of Hematology 90:10, pages 1131-1136.
Crossref
Crossref
Danelle F. James & Thomas J. Kipps. (2011) Rituximab in chronic lymphocytic leukemia. Advances in Therapy 28:7, pages 534-554.
Crossref
Crossref
Roch Houot, Holbrook Kohrt, Matthew J. Goldstein & Ronald Levy. (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer and Metastasis Reviews 30:1, pages 97-109.
Crossref
Crossref
Amy Hatfield Seung. (2010) Standard of care and novel treatments for chronic lymphocytic leukemia. American Journal of Health-System Pharmacy 67:21, pages 1813-1824.
Crossref
Crossref
Deborah A. Thomas, Susan O'Brien & Hagop M. Kantarjian. (2009) Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, pages 949-971.
Crossref
Crossref